{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:58:48Z","timestamp":1785416328630,"version":"3.56.0"},"reference-count":68,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015689","name":"GIST Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010839","name":"GIST","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010839","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jonathan David Foundation"},{"name":"University Medicine Essen Academy Clinician Scientist Program"},{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010380","name":"Stiftung Universit\u00e4tsmedizin Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX005358"],"award-info":[{"award-number":["I01BX005358"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["413570972"],"award-info":[{"award-number":["413570972"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The most common platelet-derived growth factor receptor \u03b1 (PDGFRA) alteration in gastrointestinal stromal tumors (GIST) is the exon 18 activation loop mutation D842V, which is resistant to imatinib and other type II tyrosine kinase inhibitors (TKI) but sensitive to type I TKI avapritinib. Avapritinib is FDA-approved for first-line treatment of all PDGFRA exon 18\u2013mutant GIST cases but is only available for D842V-mutant cases outside the United States. Non-D842V exon 18\u2013mutant GIST cases are understudied and lack evidence-based treatment guidelines. However, there are a few previous reports describing non-D842V exon 18\u2013mutant patients with GIST who responded well to imatinib therapy. Given that imatinib is more tolerable, globally accessible, and significantly less expensive than avapritinib, we sought to define which patients could be treated with imatinib rather than avapritinib. We assembled a cohort of more than 1,000 PDGFRA exon 18\u2013mutant GIST cases and identified that 78% of these mutations involved a key autoinhibitory aspartic acid residue at position 842. Using cell-based models, we demonstrated that imatinib sensitivity was dependent on the amino acid class of the 842-position residue, with all hydrophobic amino acids except alanine conferring resistance. In contrast, all 842-position mutations were avapritinib-sensitive. Structural modeling supported our biochemical results and revealed how 842-position mutations induce changes that can interfere with imatinib binding. Lastly, our biochemical data were validated using imatinib response data for first-line metastatic disease; patients with predicted exon 18\u2013sensitive mutations had longer progression-free survival than patients with predicted imatinib-resistant mutations. These results provide key evidence that should be used to guide therapy selection for PDGFRA-mutant GIST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Biochemical and structural modeling of PDGFRA exon 18 842-position mutations allows for the prediction of clinical TKI responses. These data can be used to generate new treatment guidelines for PDGFRA exon 18\u2013mutant GISTs and select optimal therapies for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0093","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:42:17Z","timestamp":1781196137000},"page":"1573-1591","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Clinical Sensitivities of\n                    <i>PDGFRA<\/i>\n                    Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-6712","authenticated-orcid":false,"given":"Homma M.","family":"Khosroyani","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health and Science University 1 Department of Hematology and Medical Oncology, Portland VA Health Care System and OHSU Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-8735","authenticated-orcid":false,"given":"Alina","family":"Teuber","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4198-0863","authenticated-orcid":false,"given":"Ajia","family":"Town","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health and Science University 1 Department of Hematology and Medical Oncology, Portland VA Health Care System and OHSU Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-8241","authenticated-orcid":false,"given":"Lillian R.","family":"Klug","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health and Science University 1 Department of Hematology and Medical Oncology, Portland VA Health Care System and OHSU Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-1066","authenticated-orcid":false,"given":"Denisse","family":"Evans","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05gtsta03","id-type":"ROR","asserted-by":"publisher"}],"name":"The Life Raft Group 3 , Wayne, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8241","authenticated-orcid":false,"given":"Jerry","family":"Call","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05gtsta03","id-type":"ROR","asserted-by":"publisher"}],"name":"The Life Raft Group 3 , Wayne, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-3924","authenticated-orcid":false,"given":"Sara","family":"Rothschild","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05gtsta03","id-type":"ROR","asserted-by":"publisher"}],"name":"The Life Raft Group 3 , Wayne, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":false,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 Department of Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-1435","authenticated-orcid":false,"given":"Prapassorn","family":"Thirasastr","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 Department of Sarcoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-9788","authenticated-orcid":false,"given":"Mengyuan","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-5531","authenticated-orcid":false,"given":"Ping","family":"Chi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 Department of Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-5923","authenticated-orcid":false,"given":"Peter","family":"Hohenberger","sequence":"additional","affiliation":[{"name":"5Division of Surgical Oncology, Medical Faculty Mannheim of University of Heidelberg, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qcjsm24","id-type":"ROR","asserted-by":"publisher"}],"name":"Maria Sklodowska-Curie National Research Institute of Oncology 6 Department of Soft Tissue\/Bone Sarcoma, , Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"name":"7Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium."},{"name":"8Laboratory Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-8161","authenticated-orcid":false,"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00f7hpc57","id-type":"ROR","asserted-by":"publisher"}],"name":"Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) 9 Institute of Pathology, , University Hospital Erlangen (UKER), Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-166X","authenticated-orcid":false,"given":"Mehdi","family":"Brahmi","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Cancer Research Centre of Lyon, Centre L\u00e9on B\u00e9rard, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-7023","authenticated-orcid":false,"given":"Jonathan K.","family":"Killian","sequence":"additional","affiliation":[{"name":"11Foundation Medicine Inc, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-2750","authenticated-orcid":false,"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"11Foundation Medicine Inc, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-7782","authenticated-orcid":false,"given":"Carol","family":"Beadling","sequence":"additional","affiliation":[{"name":"12Knight Diagnostic Laboratories, OHSU Knight Cancer Institute, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"13Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg- Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-7121","authenticated-orcid":false,"given":"Johanna","family":"Falkenhorst","sequence":"additional","affiliation":[{"name":"13Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg- Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-0478","authenticated-orcid":false,"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health and Science University 1 Department of Hematology and Medical Oncology, Portland VA Health Care System and OHSU Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"2026070523554300900_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00000478-199904000-00002","article-title":"Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors","volume":"23","author":"Sircar","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"2026070523554300900_bib2","first-page":"1259","article-title":"Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal","volume":"152","author":"Kindblom","year":"1998","journal-title":"Am J Pathol"},{"key":"2026070523554300900_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4293\/108680813X13693422522150","article-title":"Surgical management of gastrointestinal stromal tumors of the stomach","volume":"18","author":"Bellorin","year":"2014","journal-title":"JSLS"},{"key":"2026070523554300900_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00268-005-7944-4","article-title":"Surgical management of small gastrointestinal stromal tumors of the stomach","volume":"30","author":"Iwahashi","year":"2006","journal-title":"World J Surg"},{"key":"2026070523554300900_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s004230050264","article-title":"Surgical management of gastrointestinal stromal tumors of the stomach","volume":"385","author":"Knoop","year":"2000","journal-title":"Langenbecks Arch Surg"},{"key":"2026070523554300900_bib6","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.ijsu.2014.05.025","article-title":"Surgical management of acutely presenting gastrointestinal stromal tumors of the stomach among elderly: experience of an emergency surgery department","volume":"12 Suppl 1","author":"Marano","year":"2014","journal-title":"Int J Surg"},{"key":"2026070523554300900_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/hupa.2002.124122","article-title":"Clinical management of gastrointestinal stromal tumors: before and after STI-571","volume":"33","author":"Dematteo","year":"2002","journal-title":"Hum Pathol"},{"key":"2026070523554300900_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"2026070523554300900_bib9","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026070523554300900_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"2026070523554300900_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-022-01820-1","article-title":"TKI treatment sequencing in advanced gastrointestinal stromal tumors","volume":"83","author":"Khosroyani","year":"2023","journal-title":"Drugs"},{"key":"2026070523554300900_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070523554300900_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070523554300900_bib14","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1038\/sj.onc.1204704","article-title":"STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications","volume":"20","author":"Tuveson","year":"2001","journal-title":"Oncogene"},{"key":"2026070523554300900_bib15","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026070523554300900_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"2026070523554300900_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2026070523554300900_bib18","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38 Suppl 5","author":"Buchdunger","year":"2002","journal-title":"Eur J Cancer"},{"key":"2026070523554300900_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"2026070523554300900_bib20","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026070523554300900_bib21","first-page":"3034","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2026070523554300900_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2026070523554300900_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026070523554300900_bib24","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.20.03245","article-title":"Inhibition of KIT tyrosine kinase activity: two decades after the first approval","volume":"39","author":"Klug","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070523554300900_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/fon-2016-0192","article-title":"Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications","volume":"13","author":"Szucs","year":"2017","journal-title":"Future Oncol"},{"key":"2026070523554300900_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.06.016","article-title":"Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases","volume":"191","author":"Klug","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2026070523554300900_bib27","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J Med Chem"},{"key":"2026070523554300900_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","article-title":"Structural and biochemical studies of the PDGFRA kinase domain","volume":"477","author":"Liang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070523554300900_bib29","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Heinrich","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070523554300900_bib30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2026070523554300900_bib31","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070523554300900_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12885-021-08013-1","article-title":"Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data","volume":"21","author":"von Mehren","year":"2021","journal-title":"BMC Cancer"},{"key":"2026070523554300900_bib33","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026070523554300900_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.21037\/atm.2018.05.21","article-title":"BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor","volume":"6","author":"Schneider-Stock","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026070523554300900_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-18-1858","article-title":"Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors","volume":"25","author":"Gebreyohannes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070523554300900_bib36","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.esmoop.2021.100159","article-title":"The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation","volume":"6","author":"Trullas-Jimeno","year":"2021","journal-title":"ESMO Open"},{"key":"2026070523554300900_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","article-title":"Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain","volume":"11","author":"Grunewald","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070523554300900_bib38","volume-title":"Summary of product characteristics","author":"Blueprint Medicines (the Netherlands) B.V.: AYVAKYT\u00ae (Avapritinib)","year":"2020"},{"key":"2026070523554300900_bib39","doi-asserted-by":"crossref","first-page":"187\u2013e114","DOI":"10.1093\/oncolo\/oyac242","article-title":"Efficacy and safety of avapritinib in treating unresectable or metastatic gastrointestinal stromal tumors: a phase I\/II, open-label, multicenter study","volume":"28","author":"Li","year":"2023","journal-title":"Oncologist"},{"key":"2026070523554300900_bib40","doi-asserted-by":"crossref","first-page":"107036","DOI":"10.1016\/j.phrs.2023.107036","article-title":"Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases","volume":"199","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026070523554300900_bib41","doi-asserted-by":"crossref","first-page":"e2025866","DOI":"10.1001\/jamanetworkopen.2020.25866","article-title":"Financial implications of avapritinib for treatment of unresectable gastrointestinal stromal tumors in patients with a PDGFRA exon 18 variant or after 3 previous therapies in a hypothetical US health plan","volume":"3","author":"Proudman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026070523554300900_bib42","volume-title":"Blueprint Medicines","author":"Ayvakit. Prescribing information","year":"2020"},{"key":"2026070523554300900_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch Toxicol"},{"key":"2026070523554300900_bib44","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1002\/onco.13632","article-title":"Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors","volume":"26","author":"Joseph","year":"2021","journal-title":"Oncologist"},{"key":"2026070523554300900_bib45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2026070523554300900_bib46","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"2026070523554300900_bib47","doi-asserted-by":"crossref","first-page":"101227","DOI":"10.1016\/j.xcrm.2023.101227","article-title":"Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing","volume":"4","author":"Liu","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026070523554300900_bib48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026070523554300900_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","article-title":"Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?","volume":"37","author":"von Mehren","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2026070523554300900_bib50","doi-asserted-by":"crossref","first-page":"e438934","DOI":"10.1200\/EDBK_438934","article-title":"Leveraging patient engagement through collaboration for improved global health outcomes in sarcoma","volume":"44","author":"Evans","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070523554300900_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","article-title":"Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA","volume":"15","author":"Teuber","year":"2024","journal-title":"Nat Commun"},{"key":"2026070523554300900_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","article-title":"Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase","volume":"23","author":"Foster","year":"2004","journal-title":"J Mol Graph Model"},{"key":"2026070523554300900_bib53","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc1434","article-title":"Switching on kinases: oncogenic activation of BRAF and the PDGFR family","volume":"4","author":"Dibb","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2026070523554300900_bib54","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J Biol Chem"},{"key":"2026070523554300900_bib55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2003.08.055","article-title":"STI-571: an anticancer protein-tyrosine kinase inhibitor","volume":"309","author":"Roskoski","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070523554300900_bib56","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"2026070523554300900_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Warmuth","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2026070523554300900_bib58","doi-asserted-by":"crossref","first-page":"35488","DOI":"10.18632\/oncotarget.17828","article-title":"Ba\/F3 transformation assays","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"2026070523554300900_bib59","doi-asserted-by":"crossref","first-page":"12596","DOI":"10.18632\/oncotarget.15392","article-title":"Analysis of acquired mutations in transgenes arising in Ba\/F3 transformation assays: findings and recommendations","volume":"8","author":"Watanabe-Smith","year":"2017","journal-title":"Oncotarget"},{"key":"2026070523554300900_bib60","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2174\/092986709788682191","article-title":"Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors","volume":"16","author":"Zsila","year":"2009","journal-title":"Curr Med Chem"},{"key":"2026070523554300900_bib61","doi-asserted-by":"crossref","first-page":"109836","DOI":"10.18632\/oncotarget.22663","article-title":"Tyrosine kinase inhibitor sensitive PDGFRAlpha mutations in GIST: two cases and review of the literature","volume":"8","author":"Boonstra","year":"2017","journal-title":"Oncotarget"},{"key":"2026070523554300900_bib62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.chembiol.2018.11.005","article-title":"What makes a kinase promiscuous for inhibitors?","volume":"26","author":"Hanson","year":"2019","journal-title":"Cell Chem Biol"},{"key":"2026070523554300900_bib63","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chembiol.2010.09.010","article-title":"Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry","volume":"17","author":"Wodicka","year":"2010","journal-title":"Chem Biol"},{"key":"2026070523554300900_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2015.10.069","article-title":"Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group","volume":"52","author":"Patrikidou","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026070523554300900_bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070523554300900_bib66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2026070523554300900_bib67","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"2026070523554300900_bib68","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0093\/3803329\/crc-26-0093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1573\/3810163\/crc-26-0093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1573\/3810163\/crc-26-0093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:55:57Z","timestamp":1783310157000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1573\/786391\/Predicting-Clinical-Sensitivities-of-PDGFRA-Exon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0093","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8576497","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32904799","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904784","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904793","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904790","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904802","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904805","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904817","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904829","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32904808","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}